Thursday, May 25, 2017

Rainy Mountain begins 15-hole drilling at Brunswick

2017-05-24 15:47 ET - News Release

Mr. Douglas Mason reports
DRILLING COMMENCED ON RAINY MOUNTAIN'S BRUNSWICK GOLD EXPLORATION PROPERTY
Drilling is now under way on Rainy Mountain Royalty Corp.'s optioned Brunswick gold exploration property. The Brunswick property is accessible year-round by bush road connecting to Highway 560 that links to the west with Highway 144 and then north to Timmins (via Highway 101).  Presently, the company intends to complete 15 drill holes (10 drill sites selected on the east side of the property and five additional drill sites selected on the west side of the property). Additional drill sites are also being considered and will be determined as the current drill program continues.
 

Prior to commencement of the current drill program, Rainy Mountain continued sampling outcrops and exposures on the west side of the Brunswick property, and began trenching with a backhoe on May 9 in an attempt to expose four carbonate alteration zones associated with the recently completed induced polarization (IP) survey. The IP survey has been continued on infill lines to better define the anomalies (at 100-metre spacings using 25-metre stations and an A-spacing for the electrodes of 25 metres to obtain better resolution). The IP survey has detected the presence of sulphide mineralization within the sericite carbonate zones, which would be the normal setting for associated gold mineralization.

A magnetometer survey was also completed (with readings taken at 12.5-metre intervals), which helps outline the carbonate zones (being a low-magnetic signature) and also assists in locating diabase dikes which cross the mineralization in a northerly direction. As well, recent trenching has exposed crack seal quartz veins with sericite and hydromuscovite (apple green mica) on the fractures in the quartz, as well as disseminated sulphide zones flanking the quartz veins. The company believes that these mineral settings are favourable hosts for gold mineralization and are similar to the setting found at the Bell Creek mine in Timmins, Ont. Further, additional sampling has been done to determine the distribution of the pathfinder elements for gold (such as arsenic and antimony), which were previously detected in the fall of 2016 (see the company's news release dated Jan. 3, 2017, for additional details). Fifteen samples (of the 22 samples submitted in May, 2017) were either elevated in antimony or very anomalous, and the crack seal vein (found 200 metres west of the original antimony site) was also very anomalous in antimony. Arsenic was also detected, which is often peripheral to gold mineralization. The company believes that all of the anomalous values are geochemically significant from an exploration point of view, but are not at any toxic level. This information will assist the company in finalizing where future drill holes will be placed.

A core shack with logging tables and core saw has been set up near the property to receive and process core in a secure facility from the current drill program. Field sampling and trenching have been carried out and/or supervised by the company's qualified person, Robert Middleton, PEng, and assisted by the prospector, Michael Tremblay.

This news release has been reviewed and approved by Mr. Middleton, who is acting as the company's qualified person for the Brunswick property project, in accordance with regulations under National Instrument 43-101.
We seek Safe Harbor.

Tuesday, May 23, 2017

Hamilton Thorne signs distribution deal for BCSI tech


2017-05-23 11:05 ET - News Release

Mr. David Wolf reports
HAMILTON THORNE AND BCSI ANNOUNCE DISTRIBUTION AGREEMENT
Hamilton Thorne Ltd. and Blood Cell Storage Inc. (BCSI), a world leader in pH sensing technologies, have signed a distribution agreement for BCSI's SAFE Sens TrakStation and TrakPod technologies.

Under the terms of the new arrangement, Hamilton Thorne will offer a selection of BCSI pH monitoring solutions in the US market. Additional products, services and territories may be added to the agreement over time.

"We are pleased to expand our relationship with BCSI, the leader in pH measurement," said David Wolf, President and CEO of Hamilton Thorne. "This agreement allows us to provide monitoring solutions to existing and new customers in to the IVF community." TrakStation and TrakPod are the latest generation of continuous pH monitoring laboratory instruments from BCSI. With the capability of monitoring and logging pH data from one (1) to eight (8) chambers simultaneously, the system provides the lab manager or clinician with assurance of a stable incubator pH environment throughout the five (5) to seven (7) day IVF cycle. In contrast to systems that spot monitor pH, this unique surrogate continuous pH monitoring approach does not require opening and closing of incubator doors, thus allowing an uninterrupted incubation cycle and promoting better outcomes for IVF procedures.

The system requires no expensive calibration or adjustments during its use. One disposable sensor lasts the entire 7-day cycle and is replaced between cycles. A reusable QC alignment tool adjusts the instrument to factory specifications in under ten (10) seconds after each cycle is complete; the QC alignment tool is replaced annually.

"Hamilton Thorne is one of the most trusted suppliers of in vitro fertilization (IVF) products. They provide superior support, marketing and sales to clinics," said Russ Aldrich, CEO of BCSI. "pH is the most trusted indicator of incubation stability during the IVF process. Having the ability to measure, record and archive pH during a cycle provides the lab staff with extra assurance."

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields. Hamilton Thorne's standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics. Hamilton Thorne's growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical.
We seek Safe Harbor.